Cigarette Smoking And Psychosis: Naturalistic Follow up 4 Years After an Intervention Trial

2010 ◽  
Vol 44 (4) ◽  
pp. 342-350 ◽  
Author(s):  
Amanda Baker ◽  
Robyn Richmond ◽  
Terry J. Lewin ◽  
Frances Kay-Lambkin
Keyword(s):  
Cigarette Smoking ◽  
Psychotic Disorder ◽  
Smoking Status ◽  
Point Prevalence ◽  
Smoking Reduction ◽  
Intervention Trial ◽  
Smoking Intervention ◽  
Term Change ◽  
Point Prevalence Abstinence

Objective: Cigarette smoking is very common among people with a psychotic disorder and is often not addressed by clinicians. Additionally, few studies have evaluated smoking interventions among this group. The present study reports findings from a naturalistic follow up 4 years after a smoking intervention trial. Method: Longer-term smoking, symptomatology and functioning were examined among 247 participants (recruited in Sydney and Newcastle, Australia) who initially attended a 1 year follow up of an eight-session individually administered trial for regular smokers with a psychotic disorder. Variables profiled included continuous and point prevalence abstinence rates, smoking reduction status (no reduction, <50%, ≥50%, or abstinence) and changes in anxiety, depression and current functioning. Results: Two-thirds of those who completed the 1 year assessment were followed up at 4 years (164/247, 66.4%), of whom 79.2% reported maintenance or improvement in their smoking reduction status relative to 1 year. Abstinence at 1 year was significantly associated with 4 year point prevalence abstinence. Lengthy periods of abstinence were also evident among those reporting 4 year point prevalence abstinence or at least a 50% reduction. No baseline or intervention status variables predicted smoking status at 4 years. Symptomatology and functioning also improved between baseline and 4 years. Conclusions: Smokers with a psychotic disorder are capable of long-term change. It is recommended that clinicians address and monitor smoking during treatment of people with psychosis, emphasizing potential lifestyle and harm reduction benefits, with a view to eventual smoking cessation.

scholarly journals Association between smoking cessation and post-hospitalization healthcare costs: a matched cohort analysis

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Margaret B. Nolan ◽  
Bijan J. Borah ◽  
James P. Moriarty ◽  
David O. Warner
Keyword(s):  
Clinical Trial ◽  
Hospital Discharge ◽  
Healthcare Costs ◽  
Smoking Status ◽  
Cohort Analysis ◽  
Secondary Analysis ◽  
Population Based ◽  
Point Prevalence ◽  
Point Prevalence Abstinence

Abstract Background The potential economic benefit in terms of reduced healthcare costs when patients quit smoking after hospital discharge has not been directly measured. The aim of this study was to compare the costs for hospital admission and six-month follow-up for a cohort of patients who self-reported abstinence from cigarettes at 6 months after hospital discharge and a matched group of patients who reported continued smoking. Materials and methods This was a secondary analysis of a recent population-based clinical trial cohort (ClinicalTrials.gov ID: NCT01575145), with cohort membership determined by self-reported 7 day point prevalence abstinence at 6 months after the index hospital discharge. Participants were admitted to Mayo Clinic Hospital, Rochester, MN, between May 5, 2012 and August 10, 2014 for any indication and lived in the areas covered by postal codes included in Olmsted County, MN. Propensity score matching was used to control for differences between groups other than smoking status, and any residual imbalance was adjusted through generalized linear model with gamma distribution for cost and log-link transformation. Results Of 600 patients enrolled in the clinical trial, 144 could be contacted and self-reported 7 day point prevalence abstinence at 6 months after hospital discharge. Of these patients, 99 were successfully matched for this analysis. The cost for the index hospitalization was significantly greater in patients who abstained compared to those that did not abstain (mean difference of $3042, higher for abstainers, 95% CI $170 to $5913, P = 0.038). However, there was no difference between mean 6-month follow-up costs, number of inpatient hospitalizations, or number of emergency room visits for abstainers versus non-abstainers. Conclusion There was no evidence to support the hypothesis that abstinence at 6 months after hospital discharge is associated with a decrease in health care costs or utilization over the first 6 months after hospital discharge.

Differential Impact of Cigarette Smoking on Prognosis in Women and Men Undergoing Percutaneous Coronary Intervention

Angiology ◽  
2019 ◽  
Vol 71 (3) ◽  
pp. 281-287
Author(s):  
Li Xia Yang ◽  
Zhi Jian Wang ◽  
Dong Mei Shi ◽  
Meng Chai ◽  
Lin Zhang ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Cigarette Smoking ◽  
Smoking Status ◽  
Coronary Intervention ◽  
Major Adverse Cardiovascular Events ◽  
Target Vessel Revascularization ◽  
Percutaneous Coronary ◽  
Artery Disease

We sought to compare the effects of smoking on clinical outcomes in women and men with coronary artery disease undergoing percutaneous coronary intervention (PCI). We prospectively followed up 10 369 patients undergoing elective PCI. All patients were stratified according to smoking status and sex. The impacts of smoking on long-term major adverse cardiovascular events (MACEs, the composite of all-cause death, myocardial infarction, or target vessel revascularization) were assessed. Among 7773 men and 2596 women undergoing PCI, the prevalence of cigarette smoking was 66.7% (n = 5185) and 11.0% (n = 286; P < .001). During the 3 years of follow-up (median: 20.6 months), smoking increased MACE in both men and women (men 10.8% vs 8.1%, P < .001; women 23.2% vs 6.4%; P < .001). After adjusting for baseline characteristics, smoking had a greater effect on MACE in women (hazard ratio [HR]: 3.68, 95% confidence interval [CI]: 1.86-7.28; P < .001) compared with men (HR: 1.35, 95% CI: 1.03-1.77; P = .005, interaction P = .026). There was a lower prevalence of smoking in women compared to men among patients undergoing PCI. However, smoking confers a higher excess risk for MACE among women compared with men.

scholarly journals E-cigarette Use for Smoking Reduction and Cessation in a Four-year Follow-up Study Among Young Swiss Men: Some may Benefit, but they are Few.

2020 ◽  
Author(s):  
Gerhard Gmel ◽  
Matthias Wicki ◽  
Simon Marmet ◽  
Joseph Studer
Keyword(s):  
General Population ◽  
Negative Binomial ◽  
Smoking Status ◽  
Health Effect ◽  
Young Men ◽  
Population Level ◽  
Good Prognosis ◽  
Smoking Reduction ◽  
Beneficial Effects

Abstract BackgroundRandomised controlled trials have shown some benefits to using e-cigarettes (ECs) to facilitate smoking reduction and cessation, but real-world observational studies have rarely confirmed this. The present study looked at EC use and smoking during a four-year longitudinal study of young men. It compares general population findings with a subgroup of individuals with a good prognosis for quitting smoking. MethodsThe smoking habits of 5353 young men at t1 (average 21.3 years old) were defined as either never-smoker, ex-smoker, initiates, relapsed smoker or persistent smoker. At follow-up (t2), smoking status was analysed using logistic regression, differences in the number of cigarettes smoked by persistent t1/t2 smokers were analysed using mixed linear models and the number of quit attempts was analysed using negative binomial models. ResultsAt the general population level, EC use had no beneficial effects on reducing or ceasing smoking. Non-smokers (never- and ex-) and smokers at t1 were more likely to be smokers at t2 if they had begun to use ECs (e.g. among persistent smokers OR=4.56, 95% CI [2.75, 7.58]), but not-significantly so if they had already used ECs at t1. Among smokers at t1, almost daily EC use at t1 was associated with a non-significant reduction in smoking at t2 (OR=0.74, 95% CI [0.33, 1.65]), but occasional EC use significantly increased smoking at t2 (OR=3.05, 95% CI [2.29, 4.06]). Both daily and occasional EC use increased smoking at t2 among t1 non-smokers. T2 smokers made more attempts to quit when using ECs at t2 (IRR=1.53, 95% CI [1.26, 1.85]). Beneficial effects were found among a subgroup of EC users with a good prognosis for quitting (using nicotine liquids and at least 2nd generation ECs, motivation to quit and daily EC use at t2, but not t1). ConclusionSome smokers may have benefitted from using ECs, but they were few. At the general population level, ECs are not predominantly used in a way, which might optimise reducing or ceasing smoking. Therefore, the public health effect on the general population of using ECs may be questionable, as may policy measures to facilitate EC use.

Association of snus experimentation in late adolescence with daily cigarette smoking in early adulthood: A longitudinal study among Finnish men

2019 ◽  
Vol 48 (6) ◽  
pp. 638-645 ◽  
Author(s):  
David Araneda ◽  
Tellervo Korhonen ◽  
Tiina Laatikainen ◽  
Ari Haukkala ◽  
Richard J. Rose ◽  
...  
Keyword(s):  
Cigarette Smoking ◽  
Smoking Status ◽  
Alcohol Intoxication ◽  
Early Adulthood ◽  
Young Men ◽  
Late Adolescence ◽  
Population Based ◽  
Tobacco Product ◽  
Increased Risk

Aims: Swedish smokeless tobacco (snus) is a lower-risk tobacco product than cigarette smoking for individuals. However, the public health impact of snus use is less well studied. Critically, it is uncertain whether use of snus leads to the onset of smoking. This study aimed to investigate prospectively the association between snus experimentation in late adolescence and daily cigarette smoking in early adulthood among Finnish young men. Methods: Data were obtained from 1090 young men within the population-based FinnTwin12 cohort. At baseline (mean age 17 years), we assessed lifetime use of cigarettes and snus, plus other potential predictors of cigarette smoking. At follow-up (mean age 24 years), participants were categorized according to their current smoking status. The final analyses were conducted among 375 young men who were never smokers at baseline with adequate data on follow-up smoking status and other potential predictors of cigarette smoking. Results: Age-adjusted logistic regressions showed an increased risk of becoming a daily smoker at follow-up among those participants who had at least tried snus but had never smoked cigarettes at baseline (odds ratio (OR) 6.48, 95% confidence interval (CI) 2.02–20.7), compared with those who had never used snus. When additionally adjusted for monthly alcohol intoxication, maternal smoking, and peer drug use, the association between snus experimentation and later daily cigarette smoking was attenuated, but remained significant (OR 3.94, 95% CI 1.22–12.7). Conclusions: Our data support the proposition that snus experimentation during late adolescence is longitudinally associated with daily cigarette smoking in early adulthood. Although a causal association cannot be inferred with certainty, snus experimentation might constitute an indicator of the propensity to proceed to regular snus use and initiation of use of other tobacco or nicotine products.

Reduction and Cessation of Cigarette Smoking and Risk of Cancer: A Cohort Study of Korean Men

2008 ◽  
Vol 26 (31) ◽  
pp. 5101-5106 ◽  
Author(s):  
Yun-Mi Song ◽  
Joohon Sung ◽  
Hong-Jun Cho
Keyword(s):  
Lung Cancer ◽  
Smoking Cessation ◽  
Cigarette Smoking ◽  
Smoking Status ◽  
Smoking Reduction ◽  
Lung Cancer Patients ◽  
Asian Populations ◽  
Study Participants ◽  
Risk Of Cancer ◽  
Heavy Smokers

Purpose Reducing cigarette smoking has been proposed as a method of harm reduction. The effect of smoking reduction on cancer risk has not been studied in Asian populations. Patients and Methods A total of 479,156 Korean men, age 30 to 58 years, were stratified into nine groups based on smoking status in 1990 and 1992. From 1992 to 2003, patients were observed and tested for the occurrence of cancer. Results There was no association between smoking reduction and risk of all cancers. However, the risk of smoking-related cancers tended to decrease, though not significantly, when heavy smokers (≥ 20 cigarettes/d) became moderate smokers (10 to 19 cigarettes/d), with a hazard ratio (HR) of 0.91 (95% CI, 0.82 to 1.02). For lung cancer, patients who reduced from heavy to moderate smoking and from heavy to light smoking (< 10 cigarettes/d) had significantly decreased risks based on multivariable-adjusted HRs (HR = 0.72, 95% CI, 0.49 to 0.89; HR = 0.63, 95% CI, 0.46 to 0.84, respectively). Study participants who never smoked, sustained ex-smokers, and quitters had lower risks for all cancers, smoking-related cancers, and lung cancer in a dose-response manner as compared with heavy smokers. Conclusion Smoking reduction was associated with a significant decrease in the risk of lung cancer, but the size of risk reduction was disproportionately smaller than that expected from the reduced amount of cigarette consumption. Although smoking cessation should be the cornerstone of preventing smoking-related cancers, smoking reduction could be considered as a strategy to supplement smoking cessation for those who are unable to quit smoking immediately.

scholarly journals Decídetexto: Feasibility and Acceptability of a Mobile Smoking Cessation Intervention in Puerto Rico

2021 ◽  
Vol 18 (4) ◽  
pp. 1379
Author(s):  
Francisco Cartujano-Barrera ◽  
Cristina Peña-Vargas ◽  
Evelyn Arana-Chicas ◽  
José Pérez-Ramos ◽  
Josiemer Mattei ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Puerto Rico ◽  
Pilot Study ◽  
Self Efficacy ◽  
Text Messaging ◽  
Smoking Cessation Intervention ◽  
Point Prevalence ◽  
Cessation Intervention ◽  
Point Prevalence Abstinence

The purpose of this pilot study was to assess the feasibility and acceptability of a mobile smoking cessation intervention in Puerto Rico. This was a single-arm pilot study with 26 smokers in Puerto Rico who were enrolled in Decídetexto, a mobile smoking cessation intervention. Decídetexto incorporates three integrated components: (1) a tablet-based software that collects smoking-related information to develop an individualized quit plan, (2) a 24-week text messaging counseling program with interactive capabilities, and (3) pharmacotherapy support. Outcome measures included self-reported 7-day point prevalence abstinence at Months 3 and 6, pharmacotherapy adherence, satisfaction with the intervention, and changes in self-efficacy. The average age of the participants was 46.8 years (SD 12.7), half of them (53.8%) were female. Most participants (92.3%) smoked daily and half of them (53.8%) used menthol cigarettes. All participants requested nicotine patches at baseline. However, only 13.0% of participants used the patch >75% of days. At Month 3, 10 participants (38.4%) self-reported 7-day point prevalence abstinence (88.5% follow-up rate). At Month 6, 16 participants (61.5%) self-reported 7-day point prevalence abstinence (76.9% follow-up rate). Most participants (90%, 18/20) reported being satisfied/extremely satisfied with the intervention at Month 6. Self-efficacy mean scores significantly increased from 40.4 (SD 12.1) at baseline to 57.9 (SD 11.3) at Month 3 (p < 0.01). The study suggests that Decídetexto holds promise for further testing among Puerto Rican smokers.

Patterns of E-Cigarette Use Among Youth and Young Adults: Review of the Impact of E-Cigarettes on Cigarette Smoking

2018 ◽  
Vol 21 (10) ◽  
pp. 1320-1330 ◽  
Author(s):  
Allison Glasser ◽  
Haneen Abudayyeh ◽  
Jennifer Cantrell ◽  
Raymond Niaura
Keyword(s):  
Young Adults ◽  
Cigarette Smoking ◽  
Smoking Status ◽  
Small Sample ◽  
Future Research ◽  
Cigarette Use ◽  
Product Use ◽  
Youth And Young Adults ◽  
The Impact

Abstract There is concern that e-cigarette use among youth and young adults (YAs) may lead to future cigarette or other combustible tobacco product use. A synthesis of the literature on this topic is needed because existing longitudinal studies are limited in number and not consistent in their conclusions. We conducted a search in PubMed through December 31, 2017 for peer-reviewed studies related to e-cigarette patterns of use. Of 588 relevant studies, 26 had a youth or YA sample, were longitudinal in design, and assessed e-cigarette use at baseline and cigarette smoking at follow-up. Most studies followed a sample over time and compared cigarette smoking at follow-up between baseline e-cigarette users and nonusers. Other studies examined the difference at follow-up in cigarette smoking status among smokers according to e-cigarette use at baseline. Results suggest that, among never smokers, e-cigarette use is associated with the future (6 months to 2.5 years) cigarette trial; however, firm conclusions cannot be drawn because of limitations including small sample size, measurement of experimental use (ie, ever use, past 30-day use) rather than established use, and inadequate controls for potentially confounding variables. Conclusions also cannot be drawn from studies examining the impact of e-cigarette use among smokers due to the limited number of studies and additional limitations. A comprehensive understanding of this literature is needed to inform policy makers and consumers for evidence-based decision-making and to guide future research on e-cigarette use among youth and young adults. Implications The present article provides a review of the impact of e-cigarette use on subsequent cigarette smoking among youth and YAs. Studies presented here suggest that e-cigarette use among nonsmokers is associated with subsequent cigarette smoking, but study designs are subject to numerous limitations. Future research should focus on addressing the characteristics that put youth and YAs at the risk of using either product and how appeal and accessibility of these products are related to product use in order to inform future policy-making.

scholarly journals Varenicline in smokers with severe or very severe COPD after 24 weeks of treatment. A descriptive analysis: VALUE study

2017 ◽  
Vol 87 (3) ◽  
Author(s):  
Carlos A. Jiménez-Ruiz ◽  
Marcos Garcia Rueda ◽  
Manuel A. Martinez Muñiz ◽  
Jacobo Sellarés ◽  
Maria A. Jiménez-Fuentes ◽  
...  
Keyword(s):  
Descriptive Analysis ◽  
Point Prevalence ◽  
Open Label ◽  
Intention To Treat ◽  
Copd Patients ◽  
Continuous Abstinence ◽  
High Degree ◽  
Point Prevalence Abstinence ◽  
Severe Copd

A large number of COPD patients are smokers. The particular characteristics of this group as well as their need to quit usually require psychological counselling and pharmacological treatment to achieve abstinence and, often, intensively. Little information is available about this issue.  The main objective of the study was to evaluate the effectiveness of varenicline after 24 weeks of treatment, with continuous abstinence between weeks 9 and 24.  This study was a post-authorization, open label, observational study of prospective follow-up. Patients included were smokers with severe or very severe COPD criteria who were treated with varenicline for 24 weeks, i.e. with a 12-week extension over the usual treatment.  The outcomes in the population of subjects completing 24 weeks of follow-up were at week 24: continuous abstinence 36.8%, 7 days point prevalence abstinence 65.7%, and continuous smoking 31.5%.The outcomes in the intention-to-treat population included at baseline were: continuous abstinence 17.7% of patients, 7 days point prevalence abstinence 31.6%, continuous smoking 15.1% and not valid/unknown 51.8%.  The mean CAT score at week 24 was 15 and reduction from the baseline was 3.77 (paired T test, p<0.01). The most common adverse events reported were nausea, vivid dreams, stomach ache, insomnia, headache and vomiting.  Patients included in VALUE were active smokers despite all of them had a severe COPD which suggests a very high degree of dependence. Although the study do not allow to infer the results to the global population of smokers with severe COPD, the outcomes have shown that, at 24 weeks follow up 36.8% of the patients were successful in quitting but from 79 patients enrolled initially only 17.7% quit. 

scholarly journals Baseline Cigarette Smoking Status as a Predictor of Virologic Suppression and CD4 Cell Count During One-Year Follow-Up in Substance Users with Uncontrolled HIV Infection

2017 ◽  
Vol 22 (6) ◽  
pp. 2026-2032 ◽  
Author(s):  
Theresa Winhusen ◽  
Daniel J. Feaster ◽  
Rui Duan ◽  
Jennifer L. Brown ◽  
Eric S. Daar ◽  
...  
Keyword(s):  
Cigarette Smoking ◽  
Hiv Infection ◽  
Cell Count ◽  
Smoking Status ◽  
Virologic Suppression ◽  
Substance Users ◽  
Cd4 Cell Count ◽  
One Year ◽  
Cd4 Cell

Participant perceptions of an individualised physical activity anti-smoking intervention

2018 ◽  
Vol 118 (1) ◽  
pp. 82-95
Author(s):  
Clare Hanlon ◽  
Tony Morris ◽  
Grant Anthony O’Sullivan
Keyword(s):  
Physical Activity ◽  
Smoking Cessation ◽  
City Council ◽  
Smoking Reduction ◽  
Content Type ◽  
Smoking Intervention ◽  
Quit Smoking ◽  
The Individual ◽  
Ongoing Support

Purpose The purpose of this paper is to explore a health program comprising the individual experiences, successes and setbacks of adults in an individually tailored, community-based smoking intervention and physical activity program. The program incorporated physical activity consultation (PAC) and phone support from the well-established Quit smoking cessation program, and in partnership with Melton City Council, Victoria, Australia. Design/methodology/approach Expert facilitators in PAC led the intervention. The program was titled “ActivePlus” and the intervention was conducted for eight weeks. Post-program facilitator guidance continued for three weeks and follow-up on participants was conducted at week 24. Five participants continued to week 24 and were interviewed. Three case descriptions were chosen as a sample to analyse using descriptive content analysis to illustrate the range of experiences, successes and setbacks reported by these individual participants. Findings Smoking reduction/cessation results varied among cases, but increases in PA were sustained. Participants valued the expert support of PAC facilitators, though usage and appraisal of Quit telephone smoking cessation services was mixed. The individually tailored PAC was valued by participants, who felt it also contributed to their smoking reduction/cessation goals. Practical implications In future, the intervention would benefit from the same ongoing support in smoking cessation as the PAC. Practitioners should consider the benefit of including PAC in smoking cessation interventions. However, such interventions should be individually tailored and include facilitation by a PAC and a smoking cessation expert. Originality/value Few studies have looked at completely individualised smoking cessation interventions using PAC. The current study also addresses the recommendations of previous research to investigate the use of more intense PA intervention supported by expert PAC facilitation.

Sign in / Sign up

Export Citation Format

Share Document